Market Overview

Affymax, Takeda Announce Permanent J-Code for OMONTYS Injection In Effect

Related AFFY
AstraZeneca's Olaparib Fails to Impress FDA Panel - Analyst Blog
Herb C. Cross to Join KaloBios as Chief Financial Officer
Glaxo's Label Expansion Plans Marred as Arzerra Disappoints - Analyst Blog (Zacks)

Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for OMONTYS^® (peginesatide) Injection is now effective. This permanent OMONTYS-specific billing code, J0890, will continue to provide for streamlined reimbursement for dialysis organizations prescribing OMONTYS. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the adult dialysis patient population with chronic kidney disease (CKD) in the United States (U.S.).

Posted-In: News FDA


Related Articles (AFFY)

Around the Web, We're Loving...

Get Benzinga's Newsletters